Eli Lilly and Company Company Profile (NYSE:LLY)

About Eli Lilly and Company (NYSE:LLY)

Eli Lilly and Company logoEli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Company's Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company's human pharmaceutical products include endocrinology products, neuroscience products, oncology products, immunology products and cardiovascular products. The Company's animal health products segment includes products for food animals and products for companion animals. As of December 31, 2016, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Symbol: NYSE:LLY
  • CUSIP: 53245710
  • Web: www.lilly.com
Capitalization:
  • Market Cap: $95.08141 billion
  • Outstanding Shares: 1,055,000,000
Average Prices:
  • 50 Day Moving Avg: $84.21
  • 200 Day Moving Avg: $82.27
  • 52 Week Range: $64.18 - $89.09
P/E:
  • Trailing P/E Ratio: 37.37
  • Foreward P/E Ratio: 19.05
  • P/E Growth: 1.84
Sales & Book Value:
  • Annual Revenue: $22 billion
  • Price / Sales: 4.18
  • Book Value: $13.37 per share
  • Price / Book: 6.52
Dividend:
  • Annual Dividend: $2.08
  • Dividend Yield: 2.4%
Profitability:
  • EBITDA: $5.99 billion
  • Net Margins: 11.12%
  • Return on Equity: 28.71%
  • Return on Assets: 10.74%
Debt:
  • Debt-to-Equity Ratio: 0.70%
  • Current Ratio: 1.39%
  • Quick Ratio: 1.01%
Misc:
  • Average Volume: 3.59 million shs.
  • Beta: 0.34
  • Short Ratio: 2.62
 

Frequently Asked Questions for Eli Lilly and Company (NYSE:LLY)

What is Eli Lilly and Company's stock symbol?

Eli Lilly and Company trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."

How often does Eli Lilly and Company pay dividends? What is the dividend yield for Eli Lilly and Company?

Eli Lilly and Company announced a quarterly dividend on Monday, October 16th. Shareholders of record on Wednesday, November 15th will be paid a dividend of $0.52 per share on Friday, December 8th. This represents a $2.08 annualized dividend and a dividend yield of 2.38%. The ex-dividend date is Tuesday, November 14th. View Eli Lilly and Company's Dividend History.

How were Eli Lilly and Company's earnings last quarter?

Eli Lilly and Company (NYSE:LLY) released its earnings results on Tuesday, July, 25th. The company reported $1.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.05 by $0.06. The company had revenue of $5.82 billion for the quarter, compared to analysts' expectations of $5.60 billion. Eli Lilly and Company had a return on equity of 28.71% and a net margin of 11.12%. The business's revenue was up 7.8% compared to the same quarter last year. During the same quarter last year, the company posted $0.86 earnings per share. View Eli Lilly and Company's Earnings History.

When will Eli Lilly and Company make its next earnings announcement?

Eli Lilly and Company is scheduled to release their next quarterly earnings announcement on Tuesday, October, 24th 2017. View Earnings Estimates for Eli Lilly and Company.

What guidance has Eli Lilly and Company issued on next quarter's earnings?

Eli Lilly and Company updated its FY17 earnings guidance on Tuesday, July, 25th. The company provided earnings per share (EPS) guidance of $4.10-4.20 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.12. The company issued revenue guidance of $22.0-22.5 billion, compared to the consensus revenue estimate of $22.15 billion.

Where is Eli Lilly and Company's stock going? Where will Eli Lilly and Company's stock price be in 2017?

18 equities research analysts have issued 12-month price objectives for Eli Lilly and Company's shares. Their forecasts range from $73.00 to $105.00. On average, they expect Eli Lilly and Company's stock price to reach $90.00 in the next twelve months. View Analyst Ratings for Eli Lilly and Company.

What are analysts saying about Eli Lilly and Company stock?

Here are some recent quotes from research analysts about Eli Lilly and Company stock:

  • 1. According to Zacks Investment Research, "Lilly’s presence across a wide range of therapeutic areas and its animal health business provide support in the face of generic competition. Lilly also expects some established products like Trajenta, Forteo and Humalog to continue doing well. Lilly expects to launch 20 new products between 2014 and 2023, including the launch of at least two new indications/line extensions on an average every year. The stock has risen this year, outperforming the return from the large cap pharma industry. However, Alimta will continue to be impacted by competition. Other headwinds include competition from immuno-oncology agents as well as loss of exclusivity for many drugs in the emerging markets. Meanwhile, the recent high-profile pipeline setbacks are an investor concern. Estimates have risen slightly ahead of the company’s Q2 release. The company has a mixed record of earnings surprises in recent quarters. " (7/17/2017)
  • 2. Jefferies Group LLC analysts commented, "Date and time of first dissemination: July 17, 2017, 08:17 ET Date and time of production: July 17, 2017, 08:17 ET Target Price / Valuation Methodology: Mallinckrodt plc – MNK Our discounted cash flow (DCF) analysis leads us to a price target of $87/share for MNK shares. Our DCF considers our estimates through 2027, slowing growth through 2033 and a 10% terminal decline thereafter. In addition, we expect Mallinckrodt’s margin structure to remain somewhat consistent with our 2027 estimates. We estimate a weighted average cost of capital (WACC) of 11.4% which is in line with other companies in Mallinckrodt’s peer set due to the company’s manageable leverage and consistent cash generation potential." (7/13/2017)
  • 3. UBS AG analysts commented, "We adjust our model to account for two months of reported IMS Rx data. Key growth drivers such as Trulicity and Taltz have performed better than expected while Basaglar (insulin glargine) was modestly lower than anticipated. Our overall 2017 revenues are largely unchanged as better than expected sales (largely from the Taltz and Trulicity) offset softer than expected sales of other products, and our 2017 EPS of $4.15 remain unchanged. For 2018, our revenues went up ~$70M largely driven by Taltz and we raise our EPS to $4.45 from $4.40." (3/20/2017)

Who are some of Eli Lilly and Company's key competitors?

Who are Eli Lilly and Company's key executives?

Eli Lilly and Company's management team includes the folowing people:

  • David A. Ricks, Chairman of the Board, President, Chief Executive Officer
  • Derica W. Rice, Chief Financial Officer, Executive Vice President - Global Services
  • Jan M. Lundberg Ph.D., Executive Vice President - Science and Technology, President - Lilly Research Laboratories
  • Melissa Stapleton Barnes, Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer
  • Michael J. Harrington, Senior Vice President, General Counsel
  • Stephen F. Fry, Senior Vice President - Human Resources and Diversity
  • Enrique A. Conterno, Senior Vice President and President - Lilly Diabetes and President - Lilly USA
  • Susan Mahony Ph.D., Senior Vice President and President - Lilly Oncology
  • Barton R. Peterson, Senior Vice President - Corporate Affairs and Communications
  • Leigh Ann Pusey, Senior Vice President - Corporate Affairs and Communications

Who owns Eli Lilly and Company stock?

Eli Lilly and Company's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Fisher Asset Management LLC (0.29%), PGGM Investments (0.08%), Shell Asset Management Co. (0.04%), Private Capital Advisors Inc. (0.04%), Assenagon Asset Management S.A. (0.01%) and Verde Servicos Internacionais S.A. (0.01%). Company insiders that own Eli Lilly and Company stock include Alfonso G Zulueta, David A Ricks, Derica W Rice, Donald A Zakrowski, Enrique A Conterno, Jackson P Tai, Lilly Endowment Inc, Maria A Crowe, Melissa S Barnes, Michael J Harrington, R David Hoover, Stephen F Fry and Susan Mahony. View Institutional Ownership Trends for Eli Lilly and Company.

Who sold Eli Lilly and Company stock? Who is selling Eli Lilly and Company stock?

Eli Lilly and Company's stock was sold by a variety of institutional investors in the last quarter, including PGGM Investments, Park National Corp OH, First National Bank of Mount Dora Trust Investment Services, Verde Servicos Internacionais S.A., Quantitative Systematic Strategies LLC, Rockefeller Financial Services Inc. and Bridges Investment Counsel Inc.. Company insiders that have sold Eli Lilly and Company stock in the last year include Alfonso G Zulueta, Derica W Rice, Donald A Zakrowski, Enrique A Conterno, Lilly Endowment Inc, Melissa S Barnes, Michael J Harrington and Susan Mahony. View Insider Buying and Selling for Eli Lilly and Company.

Who bought Eli Lilly and Company stock? Who is buying Eli Lilly and Company stock?

Eli Lilly and Company's stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Fisher Asset Management LLC, Shell Asset Management Co., Wealth Enhancement Advisory Services LLC, Private Capital Advisors Inc., Curbstone Financial Management Corp, Howe & Rusling Inc. and Eqis Capital Management Inc.. Company insiders that have bought Eli Lilly and Company stock in the last two years include Jackson P Tai and R David Hoover. View Insider Buying and Selling for Eli Lilly and Company.

How do I buy Eli Lilly and Company stock?

Shares of Eli Lilly and Company can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Eli Lilly and Company's stock price today?

One share of Eli Lilly and Company stock can currently be purchased for approximately $87.23.


MarketBeat Community Rating for Eli Lilly and Company (NYSE LLY)
Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  713 (Vote Outperform)
Underperform Votes:  531 (Vote Underperform)
Total Votes:  1,244
MarketBeat's community ratings are surveys of what our community members think about Eli Lilly and Company and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Eli Lilly and Company (NYSE:LLY) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 7 Hold Ratings, 10 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $90.00 (3.18% upside)
Consensus Price Target History for Eli Lilly and Company (NYSE:LLY)
Price Target History for Eli Lilly and Company (NYSE:LLY)
Analysts' Ratings History for Eli Lilly and Company (NYSE:LLY)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/16/2017BMO Capital MarketsSet Price TargetSell$73.00N/AView Rating Details
10/13/2017Piper Jaffray CompaniesReiterated RatingBuy$105.00N/AView Rating Details
10/13/2017Barclays PLCBoost Price TargetOverweight$90.00 -> $98.00N/AView Rating Details
10/10/2017Credit Suisse GroupDowngradeOutperform -> Neutral$84.23 -> $88.00N/AView Rating Details
10/6/2017Morgan StanleySet Price TargetHold$86.00N/AView Rating Details
10/5/2017Goldman Sachs Group, Inc. (The)Reiterated RatingBuy$92.00 -> $95.00N/AView Rating Details
10/4/2017Cowen and CompanyReiterated RatingBuy$95.00LowView Rating Details
9/11/2017Jefferies Group LLCReiterated RatingBuy$89.00 -> $89.00LowView Rating Details
8/31/2017Leerink SwannReiterated RatingHoldLowView Rating Details
8/4/2017Berenberg BankReiterated RatingBuy$98.00LowView Rating Details
7/26/2017Oppenheimer Holdings, Inc.DowngradeOutperform -> Market Perform$90.00 -> $90.00LowView Rating Details
7/17/2017Deutsche Bank AGReiterated RatingBuy$90.00 -> $91.00LowView Rating Details
7/4/2017Citigroup Inc.Reiterated RatingBuy$100.00LowView Rating Details
5/21/2017Sanford C. BernsteinReiterated RatingOutperform$88.00MediumView Rating Details
4/27/2017ArgusDowngradeBuy -> Hold$64.18 -> $81.00LowView Rating Details
11/26/2016J P Morgan Chase & CoReiterated RatingOverweightN/AView Rating Details
11/25/2016Atlantic SecuritiesDowngradeOverweight -> NeutralN/AView Rating Details
10/27/2016Societe GeneraleReiterated RatingHold$78.00N/AView Rating Details
6/15/2016SunTrust Banks, Inc.Reiterated RatingBuyN/AView Rating Details
12/22/2015Bank of America CorporationReiterated RatingBuy$104.00 -> $108.00N/AView Rating Details
(Data available from 10/21/2015 forward)

Earnings

Earnings History for Eli Lilly and Company (NYSE:LLY)
Earnings by Quarter for Eli Lilly and Company (NYSE:LLY)
Earnings History by Quarter for Eli Lilly and Company (NYSE LLY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/24/2017$1.03N/AView Earnings Details
7/25/2017Q2 2017$1.05$1.11$5.60 billion$5.82 billionViewN/AView Earnings Details
4/25/2017Q1 17$0.96$0.98$5.22 billion$5.23 billionViewN/AView Earnings Details
1/31/2017Q416$0.98$0.95$5.54 billion$5.76 billionViewN/AView Earnings Details
10/25/2016Q316$0.96$0.88$4.23 billion$5.19 billionViewListenView Earnings Details
7/26/2016Q216$0.86$0.86$5.14 billion$5.40 billionViewListenView Earnings Details
4/26/2016Q116$0.85$0.83$4.82 billion$4.87 billionViewListenView Earnings Details
1/28/2016Q415$0.78$0.78$5.33 billion$5.38 billionViewListenView Earnings Details
10/22/2015Q315$0.76$0.89$4.99 billion$4.96 billionViewListenView Earnings Details
7/23/2015Q215$0.74$0.90$4.89 billion$4.98 billionViewListenView Earnings Details
4/23/2015Q115$0.76$0.87$4.62 billion$4.64 billionViewN/AView Earnings Details
1/30/2015Q414$0.74$0.75$5.21 billion$5.12 billionViewN/AView Earnings Details
10/23/2014Q314$0.66$0.66$4.83 billion$4.88 billionViewListenView Earnings Details
7/24/2014Q214$0.66$0.68$4.88 billion$4.94 billionViewN/AView Earnings Details
4/24/2014Q114$0.70$0.70$4.78 billion$4.68 billionViewN/AView Earnings Details
1/30/2014Q413$0.72$0.74$5.46 billion$5.81 billionViewListenView Earnings Details
10/23/2013Q313$1.04$1.11$5.76 billion$5.77 billionViewN/AView Earnings Details
7/24/2013Q2 2013$1.01$1.16$5.82 billion$5.93 billionViewN/AView Earnings Details
4/24/2013Q1 2013$1.05$1.14$5.66 billion$5.60 billionViewN/AView Earnings Details
1/29/2013Q4 2012$0.82$0.85$5.78 billion$5.96 billionViewN/AView Earnings Details
10/24/2012$0.82$0.79ViewN/AView Earnings Details
7/25/2012$0.76$0.83ViewN/AView Earnings Details
4/25/2012$0.80$0.92ViewN/AView Earnings Details
1/31/2012$0.80$0.87ViewN/AView Earnings Details
10/20/2011$1.12$1.13ViewN/AView Earnings Details
7/21/2011$1.18$1.18ViewN/AView Earnings Details
4/18/2011$1.16$1.24ViewN/AView Earnings Details
1/27/2011$1.10$1.11ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Eli Lilly and Company (NYSE:LLY)
2017 EPS Consensus Estimate: $4.09
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.98$0.98$0.98
Q2 20172$1.04$1.06$1.05
Q3 20173$1.01$1.06$1.04
Q4 20172$1.01$1.03$1.02
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for Eli Lilly and Company (NYSE:LLY)
Next Dividend:12/8/2017
Annual Dividend:$2.08
Dividend Yield:2.38%
Dividend Growth:1.30% (3 Year Average)
Payout Ratio:90.04% (Trailing 12 Months of Earnings)
50.12% (Based on This Year's Estimates)
45.41% (Based on Next Year's Estimates)
Track Record:2 Years of Consecutive Dividend Growth
Dividend Payments by Quarter for Eli Lilly and Company (NYSE:LLY)

Dividend History by Quarter for Eli Lilly and Company (NYSE LLY)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/16/2017quarterly$0.522.42%11/14/201711/15/201712/8/2017
6/19/2017quarterly$0.522.51%8/11/20178/15/20179/8/2017
5/1/2017quarterly$0.522.55%5/11/20175/15/20176/9/2017
12/13/2016quarterly$0.523.03%2/13/20172/15/20173/10/2017
10/17/2016quarterly$0.512.59%11/10/201611/15/201612/9/2016
6/20/2016quarterly$0.512.81%8/11/20168/15/20169/9/2016
5/2/2016quarterly$0.512.68%5/11/20165/13/20166/10/2016
12/8/2015quarterly$0.512.43%2/10/20162/12/20163/10/2016
10/19/2015quarterly$0.502.57%11/10/201511/13/201512/10/2015
6/15/2015quarterly$0.502.42%8/12/20158/14/20159/10/2015
5/4/2015quarterly$0.502.78%5/14/20155/18/20156/10/2015
12/15/2014quarterly$0.502.89%2/11/20152/13/20153/10/2015
10/20/2014quarterly$0.493.03%11/12/201411/14/201412/10/2014
6/16/2014quarterly$0.493.31%8/13/20148/15/20149/10/2014
5/5/2014quarterly$0.493.35%5/13/20145/15/20146/10/2014
12/16/2013quarterly$0.493.98%2/12/20142/14/20143/10/2014
10/21/2013quarterly$0.493.91%11/13/201311/15/201312/10/2013
6/18/2013quarterly$0.493.82%8/13/20138/15/20139/10/2013
5/6/2013quarterly$0.493.62%5/14/20135/16/20136/10/2013
12/17/2012quarterly$0.493.96%2/13/20132/15/20133/8/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Eli Lilly and Company (NYSE:LLY)
Insider Ownership Percentage: 0.20%
Institutional Ownership Percentage: 75.53%
Insider Trades by Quarter for Eli Lilly and Company (NYSE:LLY)
Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)
Insider Trades by Quarter for Eli Lilly and Company (NYSE:LLY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/4/2017Lilly Endowment IncMajor ShareholderSell205,000$86.81$17,796,050.00View SEC Filing  
9/29/2017Lilly Endowment IncMajor ShareholderSell195,000$85.14$16,602,300.00View SEC Filing  
9/15/2017Lilly Endowment IncMajor ShareholderSell190,000$82.53$15,680,700.00View SEC Filing  
8/31/2017Lilly Endowment IncMajor ShareholderSell180,000$81.06$14,590,800.00View SEC Filing  
7/31/2017Lilly Endowment IncMajor ShareholderSell220,000$83.09$18,279,800.00View SEC Filing  
6/22/2017Lilly Endowment IncMajor ShareholderSell210,000$84.43$17,730,300.00View SEC Filing  
6/20/2017Lilly Endowment IncMajor ShareholderSell215,000$83.05$17,855,750.00View SEC Filing  
6/12/2017Melissa S BarnesInsiderSell1,900$80.78$153,482.00View SEC Filing  
6/9/2017Michael J HarringtonVPSell22,833$79.97$1,825,955.01View SEC Filing  
5/4/2017Enrique A ConternoSVPSell25,000$82.76$2,069,000.00View SEC Filing  
3/30/2017Lilly Endowment IncMajor ShareholderSell210,000$84.67$17,780,700.00View SEC Filing  
2/17/2017Lilly Endowment IncMajor ShareholderSell230,000$80.27$18,462,100.00View SEC Filing  
2/6/2017Alfonso G ZuluetaSVPSell15,000$77.66$1,164,900.00View SEC Filing  
2/3/2017Derica W RiceEVPSell11,162$77.14$861,036.68View SEC Filing  
2/2/2017Donald A ZakrowskiInsiderSell2,000$77.52$155,040.00View SEC Filing  
2/1/2017Lilly Endowment IncMajor ShareholderSell220,000$77.35$17,017,000.00View SEC Filing  
12/16/2016Lilly Endowment IncMajor ShareholderSell200,000$72.59$14,518,000.00View SEC Filing  
12/16/2016Melissa S BarnesInsiderSell2,093$82.23$172,107.39View SEC Filing  
12/16/2016R David HooverDirectorBuy500$71.85$35,925.00View SEC Filing  
12/16/2016Susan MahonySVPSell20,242$72.65$1,470,581.30View SEC Filing  
10/5/2016Maria A CroweInsiderSell2,248$81.37$182,919.76View SEC Filing  
8/15/2016Jackson P TaiDirectorBuy5,773$80.43$464,322.39View SEC Filing  
8/12/2016Jackson P TaiDirectorBuy2,560$80.42$205,875.20View SEC Filing  
7/29/2016Lilly Endowment IncMajor ShareholderSell205,000$82.94$17,002,700.00View SEC Filing  
7/28/2016Donald A ZakrowskiInsiderSell1,213$83.16$100,873.08View SEC Filing  
7/28/2016Lilly Endowment IncMajor ShareholderSell240,000$82.87$19,888,800.00View SEC Filing  
7/12/2016Lilly Endowment IncMajor ShareholderSell210,000$79.54$16,703,400.00View SEC Filing  
7/7/2016Lilly Endowment IncMajor ShareholderSell225,000$79.14$17,806,500.00View SEC Filing  
6/30/2016Lilly Endowment IncMajor ShareholderSell215,000$78.46$16,868,900.00View SEC Filing  
6/29/2016Lilly Endowment IncMajor ShareholderSell220,000$77.86$17,129,200.00View SEC Filing  
6/10/2016Melissa S BarnesSVPSell992$73.77$73,179.84View SEC Filing  
5/31/2016Lilly Endowment IncMajor ShareholderSell200,000$75.12$15,024,000.00View SEC Filing  
5/12/2016Jackson P TaiDirectorBuy1,080$75.75$81,810.00View SEC Filing  
5/12/2016Lilly Endowment IncMajor ShareholderSell190,000$75.86$14,413,400.00View SEC Filing  
5/2/2016Donald A ZakrowskiCAOSell1,600$75.86$121,376.00View SEC Filing  
4/29/2016Lilly Endowment IncMajor ShareholderSell180,000$75.44$13,579,200.00View SEC Filing  
4/27/2016Alfonso G ZuluetaSVPSell12,000$76.27$915,240.00View SEC Filing  
4/8/2016Lilly Endowment IncMajor ShareholderSell200,000$74.29$14,858,000.00View SEC Filing  
2/5/2016Stephen F FrySVPSell15,230$78.87$1,201,190.10View SEC Filing  
2/3/2016David A. RicksSVPSell5,733$77.66$445,224.78View SEC Filing  
2/3/2016Derica W. RiceCFOSell10,483$77.78$815,367.74View SEC Filing  
2/1/2016Jackson P TaiDirectorBuy3,170$78.62$249,225.40View SEC Filing  
1/29/2016Alfonso G ZuluetaSVPSell5,000$78.75$393,750.00View SEC Filing  
12/21/2015Lilly Endowment IncMajor ShareholderSell205,000$86.00$17,630,000.00View SEC Filing  
12/15/2015Lilly Endowment IncMajor ShareholderSell215,000$85.60$18,404,000.00View SEC Filing  
12/9/2015Enrique A ConternoVPSell25,000$83.88$2,097,000.00View SEC Filing  
12/2/2015Lilly Endowment Incmajor shareholderSell210,000$85.09$17,868,900.00View SEC Filing  
11/20/2015Lilly Endowment Incmajor shareholderSell205,000$84.54$17,330,700.00View SEC Filing  
10/29/2015Lilly Endowment Incmajor shareholderSell200,000$82.28$16,456,000.00View SEC Filing  
10/9/2015Lilly Endowment Incmajor shareholderSell215,000$85.86$18,459,900.00View SEC Filing  
10/5/2015Lilly Endowment Incmajor shareholderSell260,000$86.46$22,479,600.00View SEC Filing  
9/18/2015Lilly Endowment Incmajor shareholderSell250,000$89.04$22,260,000.00View SEC Filing  
6/10/2015Lilly Endowment IncMajor ShareholderSell210,000$82.39$17,301,900.00View SEC Filing  
6/4/2015Lilly Endowment IncMajor ShareholderSell200,000$77.90$15,580,000.00View SEC Filing  
5/29/2015Jeffrey N SimmonsSVPSell20,000$78.08$1,561,600.00View SEC Filing  
5/20/2015Lilly Endowment IncMajor ShareholderSell190,000$73.43$13,951,700.00View SEC Filing  
5/15/2015Lilly Endowment IncMajor ShareholderSell200,000$72.83$14,566,000.00View SEC Filing  
5/8/2015Lilly Endowment IncMajor ShareholderSell195,000$73.28$14,289,600.00View SEC Filing  
5/1/2015Lilly Endowment IncMajor ShareholderSell200,000$73.09$14,618,000.00View SEC Filing  
3/30/2015Lilly Endowment IncMajor ShareholderSell180,000$73.94$13,309,200.00View SEC Filing  
3/23/2015Lilly Endowment IncMajor ShareholderSell190,000$76.97$14,624,300.00View SEC Filing  
3/9/2015Stephen F FrySVPSell4,000$69.27$277,080.00View SEC Filing  
2/4/2015David A RicksSVPSell3,147$69.99$220,258.53View SEC Filing  
2/4/2015Derica W RiceCFOSell5,316$70.00$372,120.00View SEC Filing  
2/4/2015Jan M LundbergEVPSell11,085$70.08$776,836.80View SEC Filing  
2/3/2015Jan M LundbergEVPSell121,711$70.78$8,614,704.58View SEC Filing  
2/2/2015David A RicksSVPSell4,769$71.51$341,031.19View SEC Filing  
2/2/2015Derica W RiceCFOSell10,068$71.84$723,285.12View SEC Filing  
12/4/2014Lilly Endowment IncMajor ShareholderSell190,000$71.92$13,664,800.00View SEC Filing  
12/2/2014Lilly Endowment IncMajor ShareholderSell180,000$70.14$12,625,200.00View SEC Filing  
11/13/2014Lilly Endowment IncMajor ShareholderSell200,000$67.73$13,546,000.00View SEC Filing  
11/5/2014Lilly Endowment IncMajor ShareholderSell180,000$67.00$12,060,000.00View SEC Filing  
11/4/2014Fionnuala M WalshSVPSell15,000$67.00$1,005,000.00View SEC Filing  
11/3/2014Enrique A ConternoVPSell5,000$66.03$330,150.00View SEC Filing  
10/31/2014Fionnuala M WalshSVPSell7,376$66.58$491,094.08View SEC Filing  
10/31/2014Lilly Endowment IncMajor ShareholderSell190,000$66.40$12,616,000.00View SEC Filing  
10/30/2014Lilly Endowment IncMajor ShareholderSell175,000$66.58$11,651,500.00View SEC Filing  
10/24/2014Maria A CroweInsiderSell2,750$65.77$180,867.50View SEC Filing  
10/6/2014Lilly Endowment IncMajor ShareholderSell210,000$65.63$13,782,300.00View SEC Filing  
10/1/2014Enrique A ConternoVPSell5,000$64.86$324,300.00View SEC Filing  
9/30/2014Lilly Endowment IncMajor ShareholderSell200,000$65.07$13,014,000.00View SEC Filing  
9/10/2014Lilly Endowment IncMajor ShareholderSell210,000$64.77$13,601,700.00View SEC Filing  
9/3/2014Lilly Endowment IncMajor ShareholderSell200,000$63.99$12,798,000.00View SEC Filing  
9/2/2014Enrique A ConternoVPSell5,000$63.60$318,000.00View SEC Filing  
7/29/2014Lilly Endowment IncMajor ShareholderSell250,000$63.03$15,757,500.00View SEC Filing  
7/28/2014Susan MahonySVPSell2,065$63.30$130,714.50View SEC Filing  
7/25/2014Enrique A ConternoVPSell10,000$63.79$637,900.00View SEC Filing  
7/25/2014Susan MahonySVPSell30,000$63.90$1,917,000.00View SEC Filing  
7/1/2014Lilly Endowment IncMajor ShareholderSell235,000$62.30$14,640,500.00View SEC Filing  
6/25/2014Lilly Endowment IncMajor ShareholderSell245,000$62.68$15,356,600.00View SEC Filing  
6/20/2014Lilly Endowment IncMajor ShareholderSell230,000$61.55$14,156,500.00View SEC Filing  
6/16/2014Lilly Endowment IncMajor ShareholderSell200,000$58.73$11,746,000.00View SEC Filing  
6/5/2014Lilly Endowment IncMajor ShareholderSell190,000$59.53$11,310,700.00View SEC Filing  
5/21/2014Lilly Endowment Incmajor shareholderSell230,000$58.90$13,547,000.00View SEC Filing  
5/12/2014Jackson TaiDirectorBuy17,157$59.19$1,015,522.83View SEC Filing  
5/12/2014Lilly Endowment Incmajor shareholderSell210,000$59.33$12,459,300.00View SEC Filing  
5/6/2014Lilly Endowment Incmajor shareholderSell190,000$58.79$11,170,100.00View SEC Filing  
4/29/2014Lilly Endowment Incmajor shareholderSell200,000$59.43$11,886,000.00View SEC Filing  
4/28/2014Lilly Endowment Incmajor shareholderSell150,000$58.64$8,796,000.00View SEC Filing  
8/15/2013Enrique ConternoVPSell5,000$53.79$268,950.00View SEC Filing  
7/29/2013Jacques TapieroSVPSell7,500$53.74$403,050.00View SEC Filing  
7/15/2013Enrique A ConternoVPSell5,000$51.43$257,150.00View SEC Filing  
6/17/2013Enrique A ConternoVPSell5,000$52.45$262,250.00View SEC Filing  
5/15/2013Enrique A ConternoVPSell5,000$56.15$280,750.00View SEC Filing  
5/10/2013Jeffrey N SimmonsSVPSell10,000$54.49$544,900.00View SEC Filing  
3/26/2013Susan MahonySVPSell5,000$56.00$280,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Eli Lilly and Company (NYSE:LLY)
Latest Headlines for Eli Lilly and Company (NYSE:LLY)
Source:
DateHeadline
investorplace.com logoEli Lilly (LLY) a Hold on Anemic Earnings Momentum
investorplace.com - October 20 at 11:19 AM
americanbankingnews.com logoFY2017 EPS Estimates for Eli Lilly and Company (LLY) Cut by Analyst
www.americanbankingnews.com - October 20 at 10:16 AM
finance.yahoo.com logoKen Langone on Black Monday Crash, Regulatory Landscape
finance.yahoo.com - October 20 at 4:15 AM
americanbankingnews.com logoEli Lilly and (LLY) & Its Competitors Critical Comparison
www.americanbankingnews.com - October 19 at 2:10 PM
americanbankingnews.com logoEli Lilly and Company to Post Q3 2017 Earnings of $1.01 Per Share, Jefferies Group Forecasts (LLY)
www.americanbankingnews.com - October 19 at 7:54 AM
finance.yahoo.com logoEli Lilly (LLY) to Report Q3 Earnings: What's in Store?
finance.yahoo.com - October 18 at 8:25 PM
ft.com logoEli Lilly invests in Germany’s CureVac in cancer vaccine drive
www.ft.com - October 18 at 8:24 PM
finance.yahoo.com logoLilly and CureVac Announce Global Collaboration to Develop mRNA Cancer Vaccines
finance.yahoo.com - October 18 at 8:24 PM
finance.yahoo.com logoEli Lilly to collaborate with Germany's CureVac on cancer vaccines
finance.yahoo.com - October 18 at 8:24 PM
finance.yahoo.com logoWhy Eli Lilly’s Basaglar, Jardiance, and Trajenta Could Witness Steady Growth in 2018
finance.yahoo.com - October 18 at 8:24 PM
finance.yahoo.com logoEli Lilly (LLY) to Report Q3 Earnings: What's in Store?
finance.yahoo.com - October 18 at 8:24 PM
finance.yahoo.com logoInside Eli Lilly’s Endocrinology Franchise Positioned after 1H17
finance.yahoo.com - October 18 at 8:24 PM
finance.yahoo.com logoUnderstanding Eli Lilly’s Position in Neurology Drugs after 1H17
finance.yahoo.com - October 18 at 8:24 PM
streetinsider.com logoEli Lilly & Co. (LLY) Announces New Phase 3 REVEL trial of CYRAMZA Data at 18th World Conference on Lung Cancer - StreetInsider.com
www.streetinsider.com - October 18 at 3:21 PM
nasdaq.com logoEli Lilly (LLY) to Report Q3 Earnings: What's in Store? - Nasdaq
www.nasdaq.com - October 18 at 3:21 PM
streetinsider.com logoEli Lilly & Co. (LLY) Announces Global Collaboration with CureVac to Develop mRNA Cancer Vaccines - StreetInsider.com
www.streetinsider.com - October 18 at 3:20 PM
247wallst.com logoWill Eli Lilly’s mRNA Cancer Vaccine Investment Hit Paydirt?
247wallst.com - October 18 at 2:34 PM
americanbankingnews.com logoQ3 2017 EPS Estimates for Eli Lilly and Company Raised by SunTrust Banks (LLY)
www.americanbankingnews.com - October 18 at 8:18 AM
finance.yahoo.com logoPositioning Eli Lilly’s Cardiovascular Franchise Positioned after 1H17
finance.yahoo.com - October 18 at 6:36 AM
finance.yahoo.com logoHow Eli Lilly’s Taltz Is Positioned after 1H17
finance.yahoo.com - October 18 at 6:36 AM
finance.yahoo.com logoTrump favors ex-pharma executive Azar for health secretary -Politico
finance.yahoo.com - October 18 at 6:36 AM
americanbankingnews.com logoEli Lilly and Company (LLY) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - October 17 at 3:44 AM
americanbankingnews.com logoEli Lilly and Company (LLY) Given a $73.00 Price Target at BMO Capital Markets
www.americanbankingnews.com - October 16 at 11:50 PM
rttnews.com logoEli Lilly: REVEL Data Show Efficacy Of Ramucirumab Plus Docetaxel - Quick Factsz
www.rttnews.com - October 16 at 7:59 PM
streetinsider.com logoEli Lilly & Co. (LLY) Announces New Phase 3 REVEL trial of CYRAMZA Data at 18th World Conference on Lung Cancer
www.streetinsider.com - October 16 at 7:59 PM
reuters.com logoBRIEF-Eli Lilly ‍declares Q4 dividend of $0.52/share
www.reuters.com - October 16 at 7:59 PM
finance.yahoo.com logoRapidly Progressing Advanced Non-Small Cell Lung Cancer Patients Shown to Benefit in New CYRAMZA® (ramucirumab) Phase 3 Subgroup Analysis
finance.yahoo.com - October 16 at 7:59 PM
finance.yahoo.com logoGauging Eli Lilly’s Position with Cyramza after 1H17
finance.yahoo.com - October 16 at 7:59 PM
finance.yahoo.com logoInside Eli Lilly’s Oncology Portfolio: Key Updates
finance.yahoo.com - October 16 at 7:59 PM
finance.yahoo.com logoThis Could Be Eli Lilly’s Long-Term Growth Driver
finance.yahoo.com - October 16 at 7:59 PM
finance.yahoo.com logoThe Cost Of Developing Drugs Is Insane. That Paper That Says Otherwise Is Insanely Bad
finance.yahoo.com - October 16 at 7:59 PM
finance.yahoo.com logoLilly Declares Fourth-Quarter 2017 Dividend
finance.yahoo.com - October 16 at 7:59 PM
americanbankingnews.com logoEli Lilly and Company (LLY) Plans $0.52 Quarterly Dividend
www.americanbankingnews.com - October 16 at 4:24 PM
finance.yahoo.com logoHow Eli Lilly Is Positioned after 1H17
finance.yahoo.com - October 14 at 7:55 PM
finance.yahoo.com logoThis Could Boost Eli Lilly’s Revenue Growth in 2018
finance.yahoo.com - October 14 at 7:54 PM
streetinsider.com logoEli Lilly & Co. (LLY) Says FDA Granted Priority Review for Potential New Indication for its Verzenio as Initial ... - StreetInsider.com
www.streetinsider.com - October 14 at 1:32 AM
americanbankingnews.com logoEli Lilly and Company (LLY) Price Target Increased to $98.00 by Analysts at Barclays PLC
www.americanbankingnews.com - October 13 at 5:44 PM
investorplace.com logoHold Ranking on Eli Lilly (LLY) Shares Confirmed
investorplace.com - October 13 at 10:22 AM
seekingalpha.com logoFDA grants priority review for Lilly's Verzenio as initial treatment of advanced breast cancer
seekingalpha.com - October 13 at 6:28 AM
streetinsider.com logoEli Lilly & Co. (LLY) Says FDA Granted Priority Review for Potential New Indication for its Verzenio as Initial Treatment of Advanced Breast Cancer
www.streetinsider.com - October 13 at 6:28 AM
finance.yahoo.com logoFDA Grants Priority Review for Potential New Indication for Lilly's Verzenio™ (abemaciclib) as Initial Treatment of Advanced Breast Cancer
finance.yahoo.com - October 13 at 6:27 AM
finance.yahoo.com logoFeatured Company News – Eli Lilly Announces That Verzenio Failed To Meet Primary Endpoint of Overall Survival in Phase-3 JUNIPER Study
finance.yahoo.com - October 13 at 6:27 AM
benzinga.com logo7 Catalysts For Eli Lilly Over The Next Year - Benzinga
www.benzinga.com - October 12 at 6:36 AM
barrons.com logoEli Lilly Loses Some Luster - Barron's
www.barrons.com - October 12 at 6:36 AM
streetinsider.com logoEli Lilly & Co. (LLY) Announces Topline Results from Phase 3 JUNIPER Trial Evaluating Verzenio (Abemaciclib) - StreetInsider.com
www.streetinsider.com - October 12 at 6:36 AM
finance.yahoo.com logoLilly's (LLY) Verzenio Fails in Phase III Lung Cancer Study
finance.yahoo.com - October 12 at 6:36 AM
americanbankingnews.com logoCritical Comparison: Eli Lilly and (LLY) versus Aegerion Pharmaceuticals (AEGR)
www.americanbankingnews.com - October 12 at 12:28 AM
streetinsider.com logoEli Lilly & Co. (LLY) Announces Topline Results from Phase 3 JUNIPER Trial Evaluating Verzenio (Abemaciclib)
www.streetinsider.com - October 10 at 7:55 PM
nasdaq.com logoEli Lilly: Verzenio Phase 3 JUNIPER Study Fails To Meet Primary Endpoint
www.nasdaq.com - October 10 at 7:55 PM
finance.yahoo.com logoLilly Reports Topline Results from Phase 3 JUNIPER Trial Evaluating Verzenio™ (abemaciclib) in KRAS-Mutated, Advanced Non-Small Cell Lung Cancer
finance.yahoo.com - October 10 at 7:55 PM

Social

Chart

Eli Lilly and Company (LLY) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.